Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Daliani

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Prostate Cancer|June 6, 2012
Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomyPanagiotis J Vlachostergios, Foteini Karasavvidou, Grigorios Kakkas, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 14, 2012
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cellsKonstantinos Tsapakidis, Panagiotis J Vlachostergios, Ioannis A Voutsadakis, et al.
Pathology Oncology Research : POR|July 26, 2011
p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancerPanagiotis J Vlachostergios, Foteini Karasavvidou, Anna Patrikidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1997
Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomasA H Sarris, D Daliani, R Ulmer, et al.
The Prostate|September 21, 2007
Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapiesShifeng Mao, Danai D Daliani, Xuemei Wang, et al.
Lancet (London, England)|February 24, 2001
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trialS M Tu, R E Millikan, B Mengistu, et al.
British Journal of Cancer|June 27, 2002
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumoursK Fizazi, D M Prow, K-A Do, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trialMichael A Carducci, Robert J Padley, Jurgen Breul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerChristos N Papandreou, Danai D Daliani, Darrell Nix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working GroupG J Bubley, M Carducci, W Dahut, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Prostate Cancer|June 6, 2012
Expression of neutral endopeptidase, endothelin-1, and nuclear factor kappa B in prostate cancer: interrelations and associations with prostate-specific antigen recurrence after radical prostatectomyPanagiotis J Vlachostergios, Foteini Karasavvidou, Grigorios Kakkas, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|February 14, 2012
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cellsKonstantinos Tsapakidis, Panagiotis J Vlachostergios, Ioannis A Voutsadakis, et al.
Pathology Oncology Research : POR|July 26, 2011
p53 and cyclooxygenase-2 expression are directly associated with cyclin D1 expression in radical prostatectomy specimens of patients with hormone-naïve prostate cancerPanagiotis J Vlachostergios, Foteini Karasavvidou, Anna Patrikidou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1997
Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomasA H Sarris, D Daliani, R Ulmer, et al.
The Prostate|September 21, 2007
Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapiesShifeng Mao, Danai D Daliani, Xuemei Wang, et al.
Lancet (London, England)|February 24, 2001
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trialS M Tu, R E Millikan, B Mengistu, et al.
British Journal of Cancer|June 27, 2002
Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumoursK Fizazi, D M Prow, K-A Do, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trialMichael A Carducci, Robert J Padley, Jurgen Breul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerChristos N Papandreou, Danai D Daliani, Darrell Nix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working GroupG J Bubley, M Carducci, W Dahut, et al.
Pageof 4